source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-28 08:30:00
| null |
WENZHOU, CHINA, DEC. 28, 2020 /PRNEWSWIRE/ -- ZK INTERNATIONAL GROUP CO., LTD. (NASDAQ: ZKIN) ("ZKIN", "ZK INTERNATIONAL" OR THE "COMPANY"), A DESIGNER, ENGINEER, MANUFACTURER, AND SUPPLIER OF PATENTED HIGH-PERFORMANCE STAINLESS STEEL AND CARBON STEEL PIPE PRODUCTS PRIMARILY USED FOR...
|
ZK INTERNATIONAL'S SUBSIDIARY, XSIGMA CORPORATION, COMPLETES ITS SMART CONTRACT ON THE HEELS OF BITCOIN HITTING A HIGH OF $26,700
|
ZKIN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-23 09:00:00
| null |
WENZHOU, CHINA, DEC. 23, 2020 /PRNEWSWIRE/ -- ZK INTERNATIONAL GROUP CO., LTD. (NASDAQ: ZKIN) ("ZKIN", "ZK INTERNATIONAL" OR THE "COMPANY"), A DESIGNER, ENGINEER, MANUFACTURER, AND SUPPLIER OF PATENTED HIGH-PERFORMANCE STAINLESS STEEL AND CARBON STEEL PIPE PRODUCTS PRIMARILY USED FOR...
|
ZK INTERNATIONAL GROUP VISITED BY CONSUL GENERAL AT THE U.S. CONSULATE GENERAL IN SHANGHAI
|
ZKIN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-12 10:30:00
| null |
ZK INTERNATIONAL ENTERS INTO BUDGETED $49.7 MILLION EXPANSION, SUPPLYING AND DISTRIBUTION FRAMEWORK ARRANGEMENT WITH SHANDONG HUAYE GROUP.ZK INTERNATIONAL - AGREEMENT FOR HUAYE'S ONGOING PRODUCTION LINE & MACHINE UPGRADES AND ACT AS CO'S STRATEGIC SUPPLIER & DISTRIBUTOR.ZK INTERNATIONAL - PHASE I OF UPGRADES IS EXPECTED TO BE COMPLETED BY SEPTEMBER, 2020.
|
ZK INTERNATIONAL ENTERS BUDGETED $49.7 MILLION ARRANGEMENT WITH SHANDONG HUAYE GROUP
|
ZKIN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-01-31 21:30:00
| null |
ZK INTERNATIONAL GROUP CO., LTD. ANNOUNCES RECORD REVENUE OF $63.9 MILLION FOR FISCAL FULL YEAR 2019.ZK INTERNATIONAL GROUP CO LTD - LOOKING FORWARD, DESPITE MACROECONOMIC UNCERTAINTIES, WE REMAIN CAUTIOUSLY OPTIMISTIC IN OUR GROWTH PROSPECTS.ZK INTERNATIONAL GROUP CO LTD - O LOOKING FORWARD, EXPECT STRONG ORDER BOOK TO CONTINUE TO DRIVE DOUBLE-DIGIT GROWTH IN BOTH TOP AND BOTTOM-LINES.
|
ZK INTERNATIONAL GROUP POSTS FY 2019 REVENUE OF $63.9 MLN
|
ZKIN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-19 16:30:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JULY 19, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTOR ACTION NOTICE: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-19 07:30:00
| null |
THE PHASE 3 PRIME STUDY DEMONSTRATES THAT TREATMENT WITH ZEJULA SIGNIFICANTLY EXTENDS PROGRESSION-FREE SURVIVAL VERSUS PLACEBO AND REDUCES THE RISK OF DISEASE PROGRESSION OR DEATH BY 55% FINDINGS CONFIRM THE BENEFIT OF ZEJULA MONOTHERAPY AS FIRST-LINE MAINTENANCE TREATMENT, REGARDLESS OF RESIDUAL DISEASE OR BIOMARKER STATUS, IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER
|
JAMA ONCOLOGY PUBLISHES DATA FROM ZAI LAB STUDY DEMONSTRATING SIGNIFICANT REDUCTION IN DISEASE PROGRESSION OR DEATH WITH ZEJULA (NIRAPARIB) MAINTENANCE THERAPY IN BROAD POPULATION OF ADVANCED OVARIAN CANCER PATIENTS
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-17 06:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JULY 17, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTIGATION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-17 01:03:00
| null |
SHANGHAI, CHINA AND CAMBRIDGE, MASS., JULY 17, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) AND ARGENX SE (EURONEXT & NASDAQ: ARGX) TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE ADHERE STUDY EVALUATING VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) IN ADULTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP). THE STUDY MET ITS PRIMARY ENDPOINT (P=0.000039), DEMONSTRATING A SIGNIFICANTLY LOWER RISK OF RELAPSE WITH VYVGART HYTRULO COMPARED TO PLACEBO. DETAILED DATA FROM ADHERE WILL BE PRESENTED AT AN UPCOMING MEDICAL MEETING.
|
ZAI LAB AND ARGENX REPORT POSITIVE TOPLINE DATA FROM ADHERE STUDY OF VYVGART HYTRULO IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-14 07:30:00
| null |
SHANGHAI, CHINA AND CAMBRIDGE, MASS., JULY 14, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN TREATED IN THE MAINLAND CHINA PORTION OF THE GLOBAL REGISTRATIONAL, PHASE 3 FORTITUDE-101 STUDY FOR BEMARITUZUMAB, A POTENTIAL FIRST-IN-CLASS FC-OPTIMIZED MONOCLONAL ANTIBODY THAT IS DESIGNED TO BLOCK FIBROBLAST GROWTH FACTORS FROM BINDING AND ACTIVATING FIBROBLAST GROWTH FACTOR RECEPTOR 2B (FGFR2B), INHIBITING SEVERAL DOWNSTREAM PRO-TUMOR SIGNALING PATHWAYS AND POTENTIALLY SLOWING TUMOR PROLIFERATION. FORTITUDE-101 IS A GLOBAL TRIAL OF BEMARITUZUMAB IN FIRST-LINE GASTRIC CANCER SPONSORED BY AMGEN.
|
ZAI LAB ANNOUNCES FIRST PATIENT TREATED IN MAINLAND CHINA FOR THE GLOBAL PHASE 3 FORTITUDE-101 STUDY OF BEMARITUZUMAB IN FIRST-LINE GASTRIC CANCER
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-13 07:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JULY 13, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
ONGOING INVESTIGATION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-12 14:04:00
| null |
NEW YORK , JULY 12, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR THE "COMPANY") (NASDAQ: ZLAB). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-11 07:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JULY 11, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTIGATION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-10 07:30:00
| null |
SHANGHAI, CHINA AND CAMBRIDGE, MASS., JULY 10, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THAT CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) HAS ACCEPTED THE BIOLOGICS LICENSE APPLICATION (BLA) FOR EFGARTIGIMOD ALFA INJECTION (SUBCUTANEOUS (SC) INJECTION, 1000MG (5.6ML)/VIAL) FOR THE TREATMENT OF ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG).
|
ZAI LAB ANNOUNCES ACCEPTANCE BY CHINA'S NMPA OF THE BLA FOR EFGARTIGIMOD ALFA INJECTION (SUBCUTANEOUS INJECTION) FOR PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-10 07:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JULY 10, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ: ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTIGATION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-06 16:05:00
| null |
SHANGHAI, CHINA AND CAMBRIDGE, MASS., JULY 06, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THE PROMOTION OF YAJING CHEN TO CHIEF FINANCIAL OFFICER (CFO), EFFECTIVE JULY 7, 2023. DR. CHEN, CURRENTLY ZAI LAB'S DEPUTY CFO BASED IN CAMBRIDGE, MA, HAS BEEN SUPPORTING THE COMPANY'S FINANCE FUNCTION SINCE JOINING IN SEPTEMBER 2021. SHE IS A SEASONED FINANCE EXECUTIVE WITH MORE THAN 20 YEARS OF EXPERIENCE IN THE LIFE SCIENCES INDUSTRY AS WELL AS A PH.D. TRAINED SCIENTIST. SHE SUCCEEDS BILLY CHO, WHO WILL BE STEPPING DOWN FROM HIS ROLE AND WILL BE PURSUING A SIGNIFICANT OPPORTUNITY IN PRIVATE EQUITY.
|
ZAI LAB ANNOUNCES PROMOTION OF YAJING CHEN TO CHIEF FINANCIAL OFFICER
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-06 06:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JULY 6, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
SHAREHOLDER ACTION NOTICE: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-03 23:55:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JULY 3, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTOR ACTION NOTICE: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-03 17:00:00
| null |
NEW YORK , JULY 3, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR THE "COMPANY") (NASDAQ: ZLAB). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-03 02:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JULY 3, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
SHAREHOLDER ACTION NOTICE: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-01 14:30:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JULY 1, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ: ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTIGATION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-30 16:06:00
| null |
NEW YORK , JUNE 30, 2023 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZAI LAB LIMITED (NASDAQ: ZLAB) RESULTING FROM ALLEGATIONS THAT ZAI LAB MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED ZAI LAB SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
|
ROSEN, A TOP RANKED LAW FIRM, ENCOURAGES ZAI LAB LIMITED INVESTORS TO INQUIRE ABOUT SECURITIES CLASS ACTION INVESTIGATION - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-30 13:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 30, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTIGATION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-30 09:22:00
| null |
FIRST-AND-ONLY APPROVED FCRN ANTAGONIST FOR GMG PATIENTS BY NMPA 68% OF ANTI-ACHR ANTIBODY POSITIVE GMG PATIENTS TREATED WITH VYVGART WERE RESPONDERS (N=44/65) ON THE MYASTHENIA GRAVIS ACTIVITIES OF DAILY LIVING (MG-ADL) SCALE COMPARED WITH 30% OF PATIENTS TREATED WITH PLACEBO (N=19/64) (P
|
ZAI LAB AND ARGENX ANNOUNCE APPROVAL OF VYVGART® (EFGARTIGIMOD ALFA INJECTION) FOR GENERALIZED MYASTHENIA GRAVIS IN CHINA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-28 07:30:00
| null |
SHANGHAI, CHINA AND CAMBRIDGE, MASS., JUNE 28, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THAT THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) IN CHINA HAS ACCEPTED THE NEW DRUG APPLICATION (NDA) FOR REPOTRECTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC).
|
ZAI LAB ANNOUNCES NDA ACCEPTANCE OF REPOTRECTINIB FOR PATIENTS WITH ROS1-POSITIVE NSCLC BY CHINA'S NMPA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-26 12:50:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 26, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
SHAREHOLDER ACTION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-26 05:45:00
| null |
NEW YORK , JUNE 26, 2023 /PRNEWSWIRE/ -- ATTENTION ZAI LAB LIMITED ("ZAI LAB") (NASDAQ: ZLAB) SHAREHOLDERS: THE LAW OFFICES OF VINCENT WONG ANNOUNCE THAT AN INVESTIGATION HAS COMMENCED INTO ZAI LAB AND CERTAIN OF ITS OFFICERS AND DIRECTORS REGARDING POTENTIAL SECURITIES FRAUD. THE INVESTIGATION CONCERNS, IN PART, THE BELOW: ON MARCH 9, 2022, THE U.S. SECURITIES AND EXCHANGE COMMISSION ("SEC") PUBLISHED A NOTIFICATION IDENTIFYING ZAI LAB, AMONG OTHER COMPANIES, AS IN POTENTIAL VIOLATION OF THE HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT, WHICH ALLOWS THE SEC TO DELIST COMPANIES AND BAN A COMPANY'S SHARES FROM BEING TRADED IF THE COMPANY FAILS TO ALLOW U.S. REGULATORS TO REVIEW THEIR COMPANY AUDITS FOR THREE STRAIGHT YEARS.
|
ZLAB ALERT: THE LAW OFFICES OF VINCENT WONG INVESTIGATE ZAI LAB LIMITED FOR POTENTIAL VIOLATIONS OF SECURITIES LAWS
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-23 23:30:00
| null |
NEW YORK , JUNE 23, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR THE "COMPANY") (NASDAQ: ZLAB). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-23 05:45:00
| null |
NEW YORK , JUNE 23, 2023 /PRNEWSWIRE/ -- JAKUBOWITZ LAW ANNOUNCES THAT AN INVESTIGATION INTO POTENTIAL SECURITIES FRAUD ALLEGATIONS HAS COMMENCED ON BEHALF OF SHAREHOLDERS OF ZAI LAB LIMITED (NASDAQ: ZLAB) TO BE CONTACTED BY A MEMBER OF OUR TEAM, FILL OUT THE FORM: HTTPS://CLAIMYOURLOSS.COM/SECURITIES/ZAI-LAB-CLASS-ACTION-LOSS-SUBMISSION-FORM/?ID=41209&FROM=4 FURTHER DETAILS ON THE INVESTIGATION: ON MARCH 9, 2022, THE U.S. SECURITIES AND EXCHANGE COMMISSION ("SEC") PUBLISHED A NOTIFICATION IDENTIFYING ZAI LAB, AMONG OTHER COMPANIES, AS IN POTENTIAL VIOLATION OF THE HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT, WHICH ALLOWS THE SEC TO DELIST COMPANIES AND BAN A COMPANY'S SHARES FROM BEING TRADED IF THE COMPANY FAILS TO ALLOW U.S. REGULATORS TO REVIEW THEIR COMPANY AUDITS FOR THREE STRAIGHT YEARS. ZAI LAB AND THE OTHER COMPANIES NAMED IN THE SEC NOTIFICATION HAVE UNTIL MARCH 29, 2022 TO CHALLENGE THE CHARGES AGAINST THEM.
|
ZLAB FRAUD ALERT: JAKUBOWITZ LAW IS INVESTIGATING ZAI LAB LIMITED IN CONNECTION WITH POTENTIAL VIOLATIONS OF FEDERAL SECURITIES LAWS
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-22 06:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 22, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTIGATION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-21 23:01:00
| null |
NEW YORK--(BUSINESS WIRE)-- #ACTION--BRAGAR EAGEL & SQUIRE, P.C., A NATIONALLY RECOGNIZED STOCKHOLDER RIGHTS LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ZAI LAB LIMITED (“ZAI LAB” OR THE “COMPANY”) (NASDAQ: ZLAB) ON BEHALF OF ZAI LAB STOCKHOLDERS. OUR INVESTIGATION CONCERNS WHETHER ZAI LAB HAS VIOLATED THE FEDERAL SECURITIES LAWS AND/OR ENGAGED IN OTHER UNLAWFUL BUSINESS PRACTICES. CLICK HERE TO PARTICIPATE IN THE ACTION. ON MARCH 9, 2022, THE U.S. SECURITIES AND EXCHANGE COMMISSION ("SEC") P.
|
ZAI LAB ALERT: BRAGAR EAGEL & SQUIRE, P.C. IS INVESTIGATING ZAI LAB LIMITED ON BEHALF OF ZAI LAB STOCKHOLDERS AND ENCOURAGES INVESTORS TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-21 06:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 21, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTIGATION ACTION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-21 05:45:00
| null |
NEW YORK , JUNE 21, 2023 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF ZAI LAB LIMITED: ON MARCH 9, 2022, THE U.S. SECURITIES AND EXCHANGE COMMISSION ("SEC") PUBLISHED A NOTIFICATION IDENTIFYING ZAI LAB, AMONG OTHER COMPANIES, AS IN POTENTIAL VIOLATION OF THE HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT, WHICH ALLOWS THE SEC TO DELIST COMPANIES AND BAN A COMPANY'S SHARES FROM BEING TRADED IF THE COMPANY FAILS TO ALLOW U.S. REGULATORS TO REVIEW THEIR COMPANY AUDITS FOR THREE STRAIGHT YEARS. ZAI LAB AND THE OTHER COMPANIES NAMED IN THE SEC NOTIFICATION HAVE UNTIL MARCH 29, 2022 TO CHALLENGE THE CHARGES AGAINST THEM.
|
INVESTIGATION ALERT: THE GROSS LAW FIRM NOTIFIES SHAREHOLDERS OF ZAI LAB LIMITED OF AN INVESTIGATION AND POTENTIAL CLASS ACTION LAWSUIT - (NASDAQ: ZLAB)
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-20 16:17:00
| null |
NEW YORK , JUNE 20, 2023 /PRNEWSWIRE/ -- THE KLEIN LAW FIRM ANNOUNCES THAT IT IS INVESTIGATING ALLEGATIONS THAT ZAI LAB LIMITED ("ZAI LAB") (NASDAQ: ZLAB) VIOLATED FEDERAL SECURITIES LAWS. CURRENT INVESTIGATION DETAILS:ON MARCH 9, 2022, THE U.S. SECURITIES AND EXCHANGE COMMISSION ("SEC") PUBLISHED A NOTIFICATION IDENTIFYING ZAI LAB, AMONG OTHER COMPANIES, AS IN POTENTIAL VIOLATION OF THE HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT, WHICH ALLOWS THE SEC TO DELIST COMPANIES AND BAN A COMPANY'S SHARES FROM BEING TRADED IF THE COMPANY FAILS TO ALLOW U.S. REGULATORS TO REVIEW THEIR COMPANY AUDITS FOR THREE STRAIGHT YEARS.
|
ZLAB NEWS: THE KLEIN LAW FIRM INITIATES AN INVESTIGATION INVOLVING POSSIBLE SECURITIES FRAUD VIOLATIONS BY OFFICERS OF ZAI LAB LIMITED
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-18 07:20:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 18, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
SHAREHOLDER ACTION NOTICE: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-17 11:00:00
| null |
NEW YORK , JUNE 17, 2023 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZAI LAB LIMITED (NASDAQ: ZLAB) RESULTING FROM ALLEGATIONS THAT ZAI LAB MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED ZAI LAB SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
|
ROSEN, A LEADING LAW FIRM, ENCOURAGES ZAI LAB LIMITED INVESTORS WITH LOSSES TO INQUIRE ABOUT SECURITIES CLASS ACTION INVESTIGATION - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-17 07:45:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 17, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTIGATION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-15 19:06:00
| null |
NEW YORK , JUNE 15, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR THE "COMPANY") (NASDAQ: ZLAB). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-15 06:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 15, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
SHAREHOLDER ACTION NOTICE: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100,000 TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-14 07:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 14, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
ONGOING INVESTIGATION NOTICE: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-13 07:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 13, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTIGATION ACTION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-12 22:00:00
| null |
NEW YORK , JUNE 12, 2023 /PRNEWSWIRE/ -- WHY: NEW YORK, N.Y., JUNE 10, 2023.
|
ZLAB INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, ENCOURAGES ZAI LAB LIMITED INVESTORS WITH LOSSES TO INQUIRE ABOUT SECURITIES CLASS ACTION INVESTIGATION - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-12 21:36:00
| null |
NEW YORK , JUNE 12, 2023 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF ZAI LAB LIMITED: ON MARCH 9, 2022, THE U.S. SECURITIES AND EXCHANGE COMMISSION ("SEC") PUBLISHED A NOTIFICATION IDENTIFYING ZAI LAB, AMONG OTHER COMPANIES, AS IN POTENTIAL VIOLATION OF THE HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT, WHICH ALLOWS THE SEC TO DELIST COMPANIES AND BAN A COMPANY'S SHARES FROM BEING TRADED IF THE COMPANY FAILS TO ALLOW U.S. REGULATORS TO REVIEW THEIR COMPANY AUDITS FOR THREE STRAIGHT YEARS. ZAI LAB AND THE OTHER COMPANIES NAMED IN THE SEC NOTIFICATION HAVE UNTIL MARCH 29, 2022 TO CHALLENGE THE CHARGES AGAINST THEM.
|
INVESTIGATION ALERT: THE GROSS LAW FIRM NOTIFIES SHAREHOLDERS OF ZAI LAB LIMITED OF AN INVESTIGATION AND POTENTIAL CLASS ACTION LAWSUIT - (NASDAQ: ZLAB)
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-12 20:45:00
| null |
NEW YORK , JUNE 12, 2023 /PRNEWSWIRE/ -- JAKUBOWITZ LAW ANNOUNCES THAT AN INVESTIGATION INTO POTENTIAL SECURITIES FRAUD ALLEGATIONS HAS COMMENCED ON BEHALF OF SHAREHOLDERS OF ZAI LAB LIMITED ("ZAI LAB") (NASDAQ: ZLAB). TO BE CONTACTED BY A MEMBER OF OUR TEAM, FILL OUT THE FORM: HTTPS://CLAIMYOURLOSS.COM/SECURITIES/ZAI-LAB-CLASS-ACTION-LOSS-SUBMISSION-FORM/?WIRE=4 FURTHER DETAILS ON THE INVESTIGATION: ON MARCH 9, 2022, THE U.S. SECURITIES AND EXCHANGE COMMISSION ("SEC") PUBLISHED A NOTIFICATION IDENTIFYING ZAI LAB, AMONG OTHER COMPANIES, AS IN POTENTIAL VIOLATION OF THE HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT, WHICH ALLOWS THE SEC TO DELIST COMPANIES AND BAN A COMPANY'S SHARES FROM BEING TRADED IF THE COMPANY FAILS TO ALLOW U.S. REGULATORS TO REVIEW THEIR COMPANY AUDITS FOR THREE STRAIGHT YEARS.
|
ZLAB FRAUD ALERT: JAKUBOWITZ LAW IS INVESTIGATING ZAI LAB LIMITED IN CONNECTION WITH POTENTIAL VIOLATIONS OF FEDERAL SECURITIES LAWS
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-12 20:34:00
| null |
NEW YORK , JUNE 12, 2023 /PRNEWSWIRE/ -- ATTENTION ZAI LAB LIMITED ("ZAI LAB") (NASDAQ: ZLAB) SHAREHOLDERS: THE LAW OFFICES OF VINCENT WONG ANNOUNCE THAT AN INVESTIGATION HAS COMMENCED INTO ZAI LAB AND CERTAIN OF ITS OFFICERS AND DIRECTORS REGARDING POTENTIAL SECURITIES FRAUD. THE INVESTIGATION CONCERNS, IN PART, THE BELOW: ON MARCH 9, 2022, THE U.S. SECURITIES AND EXCHANGE COMMISSION ("SEC") PUBLISHED A NOTIFICATION IDENTIFYING ZAI LAB, AMONG OTHER COMPANIES, AS IN POTENTIAL VIOLATION OF THE HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT, WHICH ALLOWS THE SEC TO DELIST COMPANIES AND BAN A COMPANY'S SHARES FROM BEING TRADED IF THE COMPANY FAILS TO ALLOW U.S. REGULATORS TO REVIEW THEIR COMPANY AUDITS FOR THREE STRAIGHT YEARS.
|
ZLAB ALERT: THE LAW OFFICES OF VINCENT WONG INVESTIGATE ZAI LAB LIMITED FOR POTENTIAL VIOLATIONS OF SECURITIES LAWS
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-12 20:27:00
| null |
NEW YORK , JUNE 12, 2023 /PRNEWSWIRE/ -- THE KLEIN LAW FIRM ANNOUNCES THAT IT IS INVESTIGATING ALLEGATIONS THAT ZAI LAB LIMITED ("ZAI LAB") (NASDAQ: ZLAB) VIOLATED FEDERAL SECURITIES LAWS. CURRENT INVESTIGATION DETAILS: ON MARCH 9, 2022, THE U.S. SECURITIES AND EXCHANGE COMMISSION ("SEC") PUBLISHED A NOTIFICATION IDENTIFYING ZAI LAB, AMONG OTHER COMPANIES, AS IN POTENTIAL VIOLATION OF THE HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT, WHICH ALLOWS THE SEC TO DELIST COMPANIES AND BAN A COMPANY'S SHARES FROM BEING TRADED IF THE COMPANY FAILS TO ALLOW U.S. REGULATORS TO REVIEW THEIR COMPANY AUDITS FOR THREE STRAIGHT YEARS.
|
ZLAB NEWS: THE KLEIN LAW FIRM INITIATES AN INVESTIGATION INVOLVING POSSIBLE SECURITIES FRAUD VIOLATIONS BY OFFICERS OF ZAI LAB LIMITED
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-12 20:23:00
| null |
NEW YORK , JUNE 12, 2023 /PRNEWSWIRE/ -- LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMMENCED AN INVESTIGATION OF ZAI LAB LIMITED ("ZAI LAB") (NASDAQ: ZLAB) CONCERNING POSSIBLE VIOLATIONS OF FEDERAL SECURITIES LAWS. ON MARCH 9, 2022, THE U.S. SECURITIES AND EXCHANGE COMMISSION ("SEC") PUBLISHED A NOTIFICATION IDENTIFYING ZAI LAB, AMONG OTHER COMPANIES, AS IN POTENTIAL VIOLATION OF THE HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT, WHICH ALLOWS THE SEC TO DELIST COMPANIES AND BAN A COMPANY'S SHARES FROM BEING TRADED IF THE COMPANY FAILS TO ALLOW U.S. REGULATORS TO REVIEW THEIR COMPANY AUDITS FOR THREE STRAIGHT YEARS.
|
ZLAB INVESTOR ALERT: LEVI & KORSINSKY, LLP NOTIFIES INVESTORS OF AN INVESTIGATION INVOLVING POSSIBLE SECURITIES FRAUD VIOLATIONS BY OFFICERS OF ZAI LAB LIMITED
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-12 11:15:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 12, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTOR ACTION NOTICE: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-10 11:20:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 10, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ: ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
SHAREHOLDER ACTION NOTICE: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-09 01:45:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 9, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ: ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTOR ACTION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-08 13:02:00
| null |
NEW YORK--(BUSINESS WIRE)--WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZAI LAB LIMITED (NASDAQ: ZLAB) RESULTING FROM ALLEGATIONS THAT ZAI LAB MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED ZAI LAB SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT. THE.
|
EQUITY ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, ENCOURAGES ZAI LAB LIMITED INVESTORS WITH LOSSES TO INQUIRE ABOUT SECURITIES CLASS ACTION INVESTIGATION – ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-08 06:00:00
| null |
LOS ANGELES, CA / ACCESSWIRE / JUNE 8, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR "THE COMPANY") (NASDAQ:ZLAB) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
INVESTOR ACTION NOTICE: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-06 14:19:00
| null |
LOS ANGELES--(BUSINESS WIRE)---- $ZLAB #ZLAB--THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM.
|
INVESTIGATION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZAI LAB LIMITED AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-06 08:05:00
| null |
TUMOR TREATING FIELDS THERAPY TOGETHER WITH STANDARD OF CARE PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL 3-MONTH IMPROVEMENT IN MEDIAN OVERALL SURVIVAL VERSUS STANDARD OF CARE WITH NO ADDED SYSTEMIC TOXICITIES
|
ZAI LAB AND NOVOCURE ANNOUNCE LUNAR PHASE 3 CLINICAL TRIAL DEMONSTRATES STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL EXTENSION IN OVERALL SURVIVAL FOR PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER AFTER PLATINUM-BASED THERAPIES
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-01 16:03:00
| null |
THREE POSTER PRESENTATIONS TO PROVIDE UPDATES ON ZAI LAB'S ONCOLOGY PROGRAMS FOCUSED ON UNRESECTABLE SOLID TUMORS, OVARIAN CANCER AND GASTROINTESTINAL STROMAL TUMORS
|
ZAI LAB TO HIGHLIGHT NEW DATA FROM ITS ONCOLOGY PIPELINE AT 2023 ASCO ANNUAL MEETING
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-18 07:30:00
| null |
SHANGHAI, CHINA AND CAMBRIDGE, MASS., MAY 18, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THAT THE CENTER FOR DRUG EVALUATION (CDE) OF CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) HAS GRANTED PRIORITY REVIEW TO REPOTRECTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC).
|
ZAI LAB ANNOUNCES THAT REPOTRECTINIB GRANTED PRIORITY REVIEW BY CHINA'S NMPA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-27 07:30:00
| null |
YL212 EXPANDS ZAI LAB'S LUNG CANCER FRANCHISE AND ENRICHES ITS GLOBAL ONCOLOGY PIPELINE WITH A POTENTIAL FIRST-IN-CLASS ADC YL212 EXPANDS ZAI LAB'S LUNG CANCER FRANCHISE AND ENRICHES ITS GLOBAL ONCOLOGY PIPELINE WITH A POTENTIAL FIRST-IN-CLASS ADC
|
ZAI LAB ANNOUNCES STRATEGIC PARTNERSHIP AND GLOBAL LICENSE AGREEMENT WITH MEDILINK THERAPEUTICS FOR A NEXT GENERATION ANTIBODY-DRUG CONJUGATE PROGRAM IN ONCOLOGY
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-26 10:25:00
| null |
SHANGHAI AND CAMBRIDGE, MASS., APRIL 26, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THAT THE RESULTS OF THE LUNAR PHASE 3 CLINICAL TRIAL IN METASTATIC, NON-SMALL CELL LUNG CANCER (NSCLC) WILL BE PRESENTED FOR THE FIRST TIME AT THE 2023 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING IN CHICAGO, TO BE HELD FROM JUNE 2 TO JUNE 6.
|
ZAI LAB ANNOUNCES PRESENTATION OF RESULTS OF THE LUNAR PHASE 3 CLINICAL TRIAL IN NON-SMALL CELL LUNG CANCER AT 2023 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-11 08:03:00
| null |
NEW TRANSLATIONAL AND CLINICAL BIOMARKER DATA FROM ZAI LAB'S GLOBAL ONCOLOGY PROGRAM ZL-1211 WILL BE FEATURED IN A POSTER PRESENTATION (ABSTRACT PRESENTATION NUMBER: 4531) NEW TRANSLATIONAL AND CLINICAL BIOMARKER DATA FROM ZAI LAB'S GLOBAL ONCOLOGY PROGRAM ZL-1211 WILL BE FEATURED IN A POSTER PRESENTATION (ABSTRACT PRESENTATION NUMBER: 4531)
|
ZAI LAB TO HIGHLIGHT NEW DATA FROM ITS ONCOLOGY PORTFOLIO AT 2023 AACR ANNUAL MEETING
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-20 06:35:00
| null |
THIRD POSITIVE REGISTRATIONAL TRIAL MET ITS PRIMARY ENDPOINT, WITH KARXT DEMONSTRATING AN 8.4-POINT REDUCTION IN PANSS TOTAL SCORE COMPARED TO PLACEBO AT WEEK 5 (P
|
ZAI LAB PARTNER KARUNA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 EMERGENT-3 TRIAL OF KARXT IN SCHIZOPHRENIA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-22 07:30:00
| null |
SHANGHAI AND CAMBRIDGE, MASS., FEB. 22, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THAT THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) IN CHINA HAS ACCEPTED THE NEW DRUG APPLICATION (NDA) FOR SULBACTAM-DURLOBACTAM (SUL-DUR), AN INVESTIGATIONAL DRUG THAT COMBINES SULBACTAM, A Β-LACTAM ANTIBIOTIC, AND DURLOBACTAM, A NOVEL BROAD-SPECTRUM Β-LACTAMASE INHIBITOR FOR THE TREATMENT OF INFECTIONS CAUSED BY ACINETOBACTER BAUMANNII, INCLUDING MULTIDRUG-RESISTANT AND CARBAPENEM-RESISTANT (CRAB) STRAINS.
|
ZAI LAB ANNOUNCES NDA ACCEPTANCE OF SULBACTAM-DURLOBACTAM (SUL-DUR) FOR INFECTIONS CAUSED BY ACINETOBACTER BAUMANNII IN CHINA BY THE NMPA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-30 07:30:00
| null |
SHANGHAI AND CAMBRIDGE, MASS., JAN. 30, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THAT THE CENTER FOR DRUG EVALUATION (CDE) OF CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) HAS GRANTED PRIORITY REVIEW STATUS TO THE NEW DRUG APPLICATION (NDA) FOR SULBACTAM-DURLOBACTAM (SUL-DUR) FOR THE TREATMENT OF INFECTIONS CAUSED BY ACINETOBACTER BAUMANNII, INCLUDING MULTIDRUG-RESISTANT AND CARBAPENEM-RESISTANT (CRAB) STRAINS.
|
ZAI LAB ANNOUNCES NDA FOR SULBACTAM-DURLOBACTAM (SUL-DUR) GRANTED PRIORITY REVIEW BY CHINA'S NMPA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-09 07:30:00
| null |
SHANGHAI AND CAMBRIDGE, MASS., JAN. 09, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THAT MICHEL VOUNATSOS HAS BEEN APPOINTED TO ITS BOARD OF DIRECTORS, EFFECTIVE JANUARY 7, 2023. MR. VOUNATSOS BRINGS TO THE BOARD EXTENSIVE GLOBAL LEADERSHIP AND MANAGEMENT EXPERIENCE IN THE BIOPHARMACEUTICAL INDUSTRY, INCLUDING MORE THAN 25 YEARS OF SERVICE AT LEADING COMPANIES. HIS EXPERTISE INCLUDES SIGNIFICANT COMMERCIAL EXPERIENCE IN CHINA AND WORLDWIDE IN THE AREAS OF PRIMARY CARE AND NEUROSCIENCE.
|
ZAI LAB APPOINTS MICHEL VOUNATSOS TO ITS BOARD OF DIRECTORS
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-05 07:34:00
| null |
THE LUNAR STUDY MET ITS PRIMARY ENDPOINT, DEMONSTRATING A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL
|
ZAI LAB AND NOVOCURE ANNOUNCE PIVOTAL LUNAR STUDY IN NON-SMALL CELL LUNG CANCER MET PRIMARY OVERALL SURVIVAL ENDPOINT
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-03 08:30:00
| null |
SHANGHAI AND CAMBRIDGE, MASS., JAN. 03, 2023 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF RAFAEL G. AMADO, M.D. AS PRESIDENT, HEAD OF GLOBAL ONCOLOGY RESEARCH AND DEVELOPMENT, EFFECTIVE DECEMBER 30, 2022. DR. AMADO BRINGS TO ZAI LAB DEEP EXPERTISE IN THE FIELD OF ONCOLOGY AND SIGNIFICANT GLOBAL BIOPHARMACEUTICAL R&D LEADERSHIP.
|
ZAI LAB ANNOUNCES THE APPOINTMENT OF DR. RAFAEL G. AMADO AS PRESIDENT, HEAD OF GLOBAL ONCOLOGY RESEARCH AND DEVELOPMENT
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-15 16:05:00
| null |
- MEDIAN OVERALL SURVIVAL (MOS) WAS NUMERICALLY LONGER FOR PATIENTS RECEIVING ZEJULA REGARDLESS OF BIOMARKER STATUS, AT 46.3 MONTHS COMPARED TO 43.4 MONTHS IN THE PLACEBO GROUP - NO NEW SAFETY ISSUES WERE IDENTIFIED
|
ZAI LAB PRESENTS INTERIM OVERALL SURVIVAL DATA FOR ZEJULA® (NIRAPARIB) FROM THE NORA PHASE 3 STUDY AT THE ESMO VIRTUAL PLENARY
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-05 18:10:00
| null |
SHANGHAI AND CAMBRIDGE, MASS., DEC. 05, 2022 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY'S PARTNER MIRATI THERAPEUTICS, INC. (NASDAQ: MRTX), A CLINICAL-STAGE ONCOLOGY COMPANY REPORTED PRELIMINARY RESULTS FROM THE KRYSTAL-7 PHASE 2 TRIAL AND KRYSTAL-1 PHASE 1B COHORT EVALUATING ADAGRASIB (400MG TWICE DAILY) CONCURRENTLY COMBINED WITH PEMBROLIZUMAB IN PATIENTS FOR THE TREATMENT OF FIRST-LINE NSCLC HARBORING A KRASG12C MUTATION ACROSS ALL PD-L1 SUBGROUPS. THESE DATA ARE THE FIRST TO DEMONSTRATE THE POTENTIAL TOLERABILITY AND FEASIBILITY OF A CONCURRENT COMBINATION REGIMEN OF A KRASG12C INHIBITOR AND A PD-1/L1 CHECKPOINT INHIBITOR.
|
ZAI LAB PARTNER MIRATI THERAPEUTICS PRESENTS LATE-BREAKING RESULTS EVALUATING CONCURRENT ADAGRASIB AND PEMBROLIZUMAB IN FIRST-LINE ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-08 07:30:00
| null |
SHANGHAI AND CAMBRIDGE, MASS., NOV. 08, 2022 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF DR. PETER HUANG AS ITS CHIEF SCIENTIFIC OFFICER (CSO), EFFECTIVE IMMEDIATELY. DR. HUANG BRINGS AN EXTENSIVE SCIENTIFIC BACKGROUND AND STRONG LEADERSHIP AND RESEARCH AND DEVELOPMENT EXPERIENCE, INCLUDING OVER 16 YEARS WORKING WITHIN THE BIOPHARMACEUTICAL INDUSTRY, TO ZAI LAB.
|
ZAI LAB ANNOUNCES THE APPOINTMENT OF DR. PETER HUANG AS CHIEF SCIENTIFIC OFFICER
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-14 07:55:00
| null |
OUTLINES COMPANY'S ESG STRATEGY THROUGH ITS TRUST FOR LIFE COMMITMENTS OUTLINES COMPANY'S ESG STRATEGY THROUGH ITS TRUST FOR LIFE COMMITMENTS
|
ZAI LAB LAUNCHES ITS FIRST TRUST REPORT
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-27 08:00:00
| null |
-- ZAI LAB OBTAINS EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE TIVDAK, AN FDA-APPROVED FIRST-IN-CLASS ANTIBODY-DRUG CONJUGATE (ADC), IN MAINLAND CHINA, HONG KONG, MACAU, AND TAIWAN -- -- ZAI LAB WILL LEVERAGE ITS LEADERSHIP IN WOMEN'S CANCER IN CHINA TO COMMERCIALIZE AND EXPAND PATIENT ACCESS TO TIVDAK --
|
SEAGEN AND ZAI LAB ANNOUNCE REGIONAL STRATEGIC COLLABORATION AND LICENSE AGREEMENT FOR TIVDAK® (TISOTUMAB VEDOTIN-TFTV)
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-08 07:02:00
| null |
TRIAL MET PRIMARY ENDPOINT, WITH KARXT DEMONSTRATING A STATISTICALLY SIGNIFICANT 9.6-POINT REDUCTION IN PANSS TOTAL SCORE COMPARED TO PLACEBO AT WEEK 5 (P
|
ZAI LAB PARTNER KARUNA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 EMERGENT-2 TRIAL OF KARXT IN SCHIZOPHRENIA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-24 23:55:00
| null |
SHANGHAI , JULY 24, 2022 /PRNEWSWIRE/ -- QIMING VENTURE PARTNERS' PORTFOLIO COMPANY INVENTISBIO (SHSE: 688382), A LEADING COMPANY IN INNOVATIVE DRUG DEVELOPMENT, TODAY LISTED ON THE SCIENCE AND TECHNOLOGY INNOVATION BOARD (THE "STAR MARKET") OF THE SHANGHAI STOCK EXCHANGE. THE ISSUE PRICE IS CNY 18.12 PER SHARE, REPRESENTING A MARKET CAP OF CNY 10.419 BILLION.
|
QIMING'S PORTFOLIO COMPANY INVENTISBIO LISTS ON STAR MARKET
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-17 20:00:00
| null |
SHANGHAI, SAN FRANCISCO, AND CAMBRIDGE, MASS., JULY 17, 2022 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, ANNOUNCED, EFFECTIVE TODAY, THAT ITS ORDINARY SHARES TRADED ON THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “HONG KONG STOCK EXCHANGE”) ARE NOW INCLUDED IN THE SHANGHAI-HONG KONG STOCK CONNECT PROGRAM. SIMILARLY, ZAI LAB'S ORDINARY SHARES TRADED ON THE HONG KONG STOCK EXCHANGE HAVE BEEN INCLUDED IN THE SHENZHEN-HONG KONG STOCK CONNECT PROGRAM SINCE JUNE OF 2022 WHEN THE COMPANY'S DUAL PRIMARY LISTING ON BOTH NASDAQ AND THE HONG KONG STOCK EXCHANGE BECAME EFFECTIVE. BOTH STOCK CONNECT PROGRAMS ARE ANTICIPATED TO INCREASE THE ACCESS THAT ELIGIBLE INVESTORS IN MAINLAND CHINA HAVE TO ZAI LAB AND ITS SHARES.
|
ZAI LAB ANNOUNCES INCLUSION OF ITS ORDINARY SHARES IN TWO STOCK CONNECT PROGRAMS
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-13 07:30:00
| null |
EFGARTIGIMOD ALFA INJECTION IS THE FIRST ACCEPTED BLA SUBMISSION OF AN FCRN ANTAGONIST FOR GMG PATIENTS IN CHINA EFGARTIGIMOD ALFA INJECTION IS THE FIRST ACCEPTED BLA SUBMISSION OF AN FCRN ANTAGONIST FOR GMG PATIENTS IN CHINA
|
ZAI LAB ANNOUNCES ACCEPTANCE BY CHINA'S NMPA OF THE BLA FOR EFGARTIGIMOD FOR PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-27 00:00:00
| null |
– FIRST COMPANY TO CONVERT FROM SECONDARY TO PRIMARY LISTING STATUS IN HONG KONG
|
ZAI LAB ANNOUNCES PRIMARY LISTING ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-10 07:30:00
| null |
-- BREAKTHROUGH THERAPY DESIGNATIONS GRANTED FOR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS PRETREATED WITH ONE PRIOR LINE OF ROS1 TYROSINE KINASE INHIBITOR (TKI) WITH OR WITHOUT PRIOR CHEMOTHERAPY
|
ZAI LAB ANNOUNCES BREAKTHROUGH THERAPY DESIGNATIONS GRANTED FOR REPOTRECTINIB IN CHINA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-03 08:00:00
| null |
CONFIRMED OBJECTIVE RESPONSE RATE WAS 50% FOR PATIENTS TREATED WITH TTFIELDS TOGETHER WITH STANDARD-OF-CARE CHEMOTHERAPY
|
ZAI LAB AND NOVOCURE ANNOUNCE EF-31 PHASE 2 PILOT STUDY EVALUATING TUMOR TREATING FIELDS TOGETHER WITH STANDARD-OF-CARE CHEMOTHERAPY MEETS PRIMARY ENDPOINT FOR FIRST-LINE TREATMENT OF GASTRIC CANCER
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-20 16:01:00
| null |
SHANGHAI AND SAN FRANCISCO AND CAMBRIDGE, MASS., MAY 20, 2022 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT, DUE TO THE PUBLIC HEALTH IMPACT OF THE CORONAVIRUS (COVID-19) PANDEMIC AND THE RECENT PANDEMIC-RELATED RESTRICTIONS IN SHANGHAI, THE FORMAT OF THE 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS (ANNUAL MEETING) OF ZAI LAB LIMITED HAS BEEN CHANGED, AND THE ANNUAL MEETING WILL BE HELD IN A VIRTUAL MEETING FORMAT ONLY. THE PURPOSE OF THE ANNUAL MEETING IS TO CONSIDER AND VOTE ON THE MATTERS DESCRIBED IN THE PROXY STATEMENT. AS PREVIOUSLY ANNOUNCED, THE ANNUAL MEETING WILL BE HELD ON JUNE 22, 2022 AT 8:00 A.M. (U.S. EASTERN TIME) / 8:00 P.M. (SHANGHAI AND HONG KONG TIME).
|
ZAI LAB ANNOUNCES CHANGE TO VIRTUAL 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 22, 2022
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-05 11:55:00
| null |
- STUDY MET PRIMARY ENDPOINT, DEMONSTRATING A HIGHER PROPORTION OF SUSTAINED PLATELET RESPONSE WITH VYVGART TREATMENT COMPARED TO PLACEBO (P=0.0316); RESPONDERS OBSERVED ACROSS PATIENT TYPES REGARDLESS OF PRIOR THERAPY OR DISEASE SEVERITY
|
ZAI LAB PARTNER ARGENX ANNOUNCES POSITIVE PHASE 3 DATA FROM ADVANCE TRIAL OF VYVGART® (EFGARTIGIMOD ALFA-FCAB) IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-28 07:30:00
| null |
SHANGHAI AND SAN FRANCISCO AND CAMBRIDGE, MASS. AND SAN DIEGO, APRIL 28, 2022 (GLOBE NEWSWIRE) -- ZAI LAB (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, AND TURNING POINT THERAPEUTICS, INC. (NASDAQ: TPTX), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY DEVELOPING NEXT-GENERATION THERAPIES THAT TARGET GENETIC DRIVERS OF CANCER, TODAY ANNOUNCED TOPLINE DATA FOR REPOTRECTINIB WITHIN THE CHINA REGION FROM THE PREVIOUSLY DISCLOSED PHASE 1/2 TRIDENT-1 STUDY DATASET.
|
ZAI LAB AND TURNING POINT THERAPEUTICS ANNOUNCE TOPLINE ANALYSIS IN CHINA SUBPOPULATION FOR REPOTRECTINIB IN ROS1-POSITIVE NSCLC COHORTS WITHIN GLOBAL PHASE 1/2 TRIDENT-1 STUDY
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-21 07:30:00
| null |
ZAI LAB'S ENGAGEMENT OF AN AUDIT FIRM LOCATED IN THE UNITED STATES IS EXPECTED TO FACILITATE THE COMPANY'S CONTINUED LISTING ON NASDAQ BECAUSE KPMG IS SUBJECT TO INSPECTION BY THE PCAOB ZAI LAB'S ENGAGEMENT OF AN AUDIT FIRM LOCATED IN THE UNITED STATES IS EXPECTED TO FACILITATE THE COMPANY'S CONTINUED LISTING ON NASDAQ BECAUSE KPMG IS SUBJECT TO INSPECTION BY THE PCAOB
|
ZAI LAB ANNOUNCES ENGAGEMENT OF KPMG LLP, A U.S. AUDITOR, AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-18 18:30:00
| null |
NEW YORK , APRIL 18, 2022 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZAI LAB LIMITED (NASDAQ: ZLAB) RESULTING FROM ALLEGATIONS THAT ZAI LAB MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED ZAI LAB SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
|
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, ENCOURAGES ZAI LAB LIMITED INVESTORS WITH LOSSES TO INQUIRE ABOUT SECURITIES CLASS ACTION INVESTIGATION - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-07 14:55:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - APRIL 7, 2022) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZAI LAB LIMITED (NASDAQ: ZLAB) RESULTING FROM ALLEGATIONS THAT ZAI LAB MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.SO WHAT: IF YOU PURCHASED ZAI LAB SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES...
|
ZLAB INVESTOR NOTICE: ROSEN, A LEADING LAW FIRM, ENCOURAGES ZAI LAB LIMITED INVESTORS WITH LOSSES TO INQUIRE ABOUT SECURITIES CLASS ACTION INVESTIGATION - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-04 16:20:00
| null |
NEW YORK , APRIL 4, 2022 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZAI LAB LIMITED (NASDAQ: ZLAB) RESULTING FROM ALLEGATIONS THAT ZAI LAB MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED ZAI LAB SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
|
ZLAB INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, ENCOURAGES ZAI LAB LIMITED INVESTORS WITH LOSSES TO INQUIRE ABOUT SECURITIES CLASS ACTION INVESTIGATION - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-03 20:45:00
| null |
NEW YORK , APRIL 3, 2022 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR THE "COMPANY") (NASDAQ: ZLAB). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-01 15:03:00
| null |
LOS ANGELES--(BUSINESS WIRE)---- $ZLAB #ZLAB--THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN ZAI LAB LIMITED WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
INVESTIGATION ALERT: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN ZAI LAB LIMITED WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-31 12:56:00
| null |
NEW YORK--(BUSINESS WIRE)--WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZAI LAB LIMITED (NASDAQ: ZLAB) RESULTING FROM ALLEGATIONS THAT ZAI LAB MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED ZAI LAB SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT. THE
|
EQUITY ALERT: ROSEN LAW FIRM ENCOURAGES ZAI LAB LIMITED INVESTORS WITH LOSSES IN EXCESS OF $100K TO INQUIRE ABOUT SECURITIES CLASS ACTION INVESTIGATION – ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-26 00:45:00
| null |
NEW YORK , MARCH 26, 2022 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR THE "COMPANY") (NASDAQ: ZLAB). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-23 14:45:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - MARCH 23, 2022) - POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR THE "COMPANY") (NASDAQ: ZLAB). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S. WILLOUGHBY AT NEWACTION@POMLAW.COM OR 888-476-6529, EXT. 7980.THE INVESTIGATION CONCERNS WHETHER ZAI LAB AND CERTAIN OF ITS OFFICERS AND/OR DIRECTORS HAVE ENGAGED IN SECURITIES FRAUD OR OTHER UNLAWFUL BUSINESS PRACTICES. [CLICK HERE FOR INFORMATION...
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-23 07:30:00
| null |
SHANGHAI AND SAN FRANCISCO, AND CAMBRIDGE, MASS., MARCH 23, 2022 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT, DUE TO THE PUBLIC HEALTH IMPACT OF THE CORONAVIRUS (COVID-19) PANDEMIC AND THE RECENT PANDEMIC-RELATED RESTRICTIONS IN SHANGHAI, THE FORMAT OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS (EGM) OF ZAI LAB LIMITED HAS BEEN CHANGED AND WILL BE HELD IN A VIRTUAL MEETING FORMAT ONLY. THE PURPOSE OF THE EGM IS TO CONSIDER AND VOTE ON A PROPOSAL RELATING TO A PROPOSED 1-TO-10 SHARE SUBDIVISION OF THE ORDINARY SHARES OF ZAI LAB LIMITED. AS PREVIOUSLY ANNOUNCED, THE EGM WILL BE HELD ON MARCH 28, 2022 AT 8:00 A.M. (U.S. EASTERN TIME) / 8:00 P.M. (HONG KONG TIME).
|
ZAI LAB ANNOUNCES CHANGE TO VIRTUAL EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 28, 2022
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-20 20:00:00
| null |
SHANGHAI AND SAN FRANCISCO AND CAMBRIDGE, MASS., MARCH 20, 2022 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY PRESENTED DATA FROM THE PHASE 3 PRIME STUDY OF ZEJULA (NIRAPARIB) AS MAINTENANCE THERAPY AT THE SOCIETY OF GYNECOLOGIC ONCOLOGY ANNUAL MEETING. ZEJULA DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION-FREE SURVIVAL (PFS) WITH A TOLERABLE SAFETY PROFILE IN CHINESE PATIENTS WITH NEWLY DIAGNOSED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (COLLECTIVELY TERMED AS OVARIAN CANCER) FOLLOWING A RESPONSE TO PLATINUM-BASED CHEMOTHERAPY, REGARDLESS OF BIOMARKER STATUS.
|
ZAI LAB PRESENTS POSITIVE RESULTS FROM PHASE 3 PRIME STUDY OF ZEJULA® (NIRAPARIB) AT SOCIETY OF GYNECOLOGIC ONCOLOGY MEETING
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-18 10:25:00
| null |
ATLANTA, GEORGIA--(NEWSFILE CORP. - MARCH 18, 2022) - HOLZER & HOLZER, LLC IS INVESTIGATING WHETHER ZAI LAB LIMITED ("ZAI LAB" OR THE "COMPANY") (NASDAQ: ZLAB) COMPLIED WITH FEDERAL SECURITIES LAWS. ON MARCH 9, 2022, THE SEC PUBLISHED A NOTIFICATION IDENTIFYING ZAI LAB, AMONG OTHERS, AS BEING IN POTENTIAL VIOLATION OF THE HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT. FOLLOWING THIS NEWS, THE COMPANY'S STOCK PRICE DROPPED. IF YOU PURCHASED ZAI LAB STOCK AND SUFFERED A LOSS ON...
|
SHAREHOLDER ALERT: INVESTIGATION OF ZAI LAB (ZLAB) ANNOUNCED BY HOLZER & HOLZER, LLC
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-16 20:35:00
| null |
NEW YORK , MARCH 16, 2022 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR THE "COMPANY") (NASDAQ: ZLAB). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-15 20:26:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - MARCH 15, 2022) - POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED ("ZAI LAB" OR THE "COMPANY") (NASDAQ: ZLAB). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S. WILLOUGHBY AT NEWACTION@POMLAW.COM OR 888-476-6529, EXT. 7980.THE INVESTIGATION CONCERNS WHETHER ZAI LAB AND CERTAIN OF ITS OFFICERS AND/OR DIRECTORS HAVE ENGAGED IN SECURITIES FRAUD OR OTHER UNLAWFUL BUSINESS PRACTICES. [CLICK HERE FOR INFORMATION...
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZAI LAB LIMITED - ZLAB
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-15 07:30:00
| null |
SHANGHAI AND SAN FRANCISCO AND CAMBRIDGE, MASS., MARCH 15, 2022 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF JOSH SMILEY AS ITS CHIEF OPERATING OFFICER (COO). MR. SMILEY BRINGS OVER 26 YEARS OF EXPERIENCE WORKING WITHIN THE BIOPHARMACEUTICAL INDUSTRY, INCLUDING EXPERIENCE LEADING FINANCE, CORPORATE STRATEGY, BUSINESS DEVELOPMENT, VENTURE CAPITAL AND THE GLOBAL BUSINESS SERVICES OPERATIONS AT ELI LILLY AND CO (LILLY).
|
ZAI LAB ANNOUNCES THE APPOINTMENT OF JOSH SMILEY AS CHIEF OPERATING OFFICER
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-17 07:30:00
| null |
--- POTENTIAL BEST-IN-CLASS THERAPY FOR ROS1-POSITIVE METASTATIC NSCLC AND ADVANCED SOLID TUMORS --- POTENTIAL BEST-IN-CLASS THERAPY FOR ROS1-POSITIVE METASTATIC NSCLC AND ADVANCED SOLID TUMORS
|
ZAI LAB ANNOUNCES BREAKTHROUGH THERAPY DESIGNATION GRANTED FOR REPOTRECTINIB IN CHINA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-12 07:30:00
| null |
SHANGHAI, SAN FRANCISCO, AND CAMBRIDGE, MASS., JAN. 12, 2022 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED TREATMENT OF THE FIRST PATIENT IN GREATER CHINA IN THE PANOVA-3 TRIAL, A PHASE 3 PIVOTAL TRIAL OF TUMOR TREATING FIELDS IN PATIENTS WITH PANCREATIC CANCER.
|
ZAI LAB ANNOUNCES FIRST PATIENT TREATED IN GREATER CHINA IN PANOVA-3 PHASE 3 PIVOTAL TRIAL OF TUMOR TREATING FIELDS IN PANCREATIC CANCER
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-06 07:30:00
| null |
SHANGHAI AND SAN FRANCISCO AND CAMBRIDGE, MASS., JAN. 06, 2022 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) HAS ACCEPTED THE NEW DRUG APPLICATION (NDA) FOR MARGETUXIMAB, AN INVESTIGATIONAL, FC-ENGINEERED MONOCLONAL ANTIBODY THAT TARGETS HER2. THE MARGETUXIMAB NDA IS FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 REGIMENS, AT LEAST ONE OF WHICH WAS FOR METASTATIC DISEASE, IN COMBINATION WITH CHEMOTHERAPY.
|
ZAI LAB ANNOUNCES NDA ACCEPTANCE OF MARGETUXIMAB FOR PATIENTS WITH PRETREATED METASTATIC HER2-POSITIVE BREAST CANCER IN CHINA BY THE NMPA
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-22 07:30:00
| null |
SHANGHAI AND SAN FRANCISCO AND CAMBRIDGE, MASS., DEC. 22, 2021 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE PROMOTION OF HARALD REINHART, M.D., FROM HIS CURRENT ROLE AS CHIEF MEDICAL OFFICER (CMO) TO PRESIDENT AND HEAD OF GLOBAL DEVELOPMENT FOR NEUROSCIENCE, AUTOIMMUNE AND INFECTIOUS DISEASES. DR. REINHART HAS BEEN WITH THE COMPANY SINCE INCEPTION, FIRST AS AN ADVISOR AND SINCE 2017, AS CHIEF MEDICAL OFFICER RESPONSIBLE FOR THE AUTOIMMUNE AND INFECTIOUS DISEASES PORTFOLIO.
|
ZAI LAB ANNOUNCES PROMOTION OF HARALD REINHART, M.D. TO PRESIDENT AND HEAD OF GLOBAL DEVELOPMENT, NEUROSCIENCE, AUTOIMMUNE AND INFECTIOUS DISEASES
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-17 18:09:00
| null |
SHANGHAI AND SAN FRANCISCO AND CAMBRIDGE, MASS., DEC. 17, 2021 (GLOBE NEWSWIRE) -- ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688), A PATIENT-FOCUSED, INNOVATIVE, COMMERCIAL-STAGE, GLOBAL BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT ITS PARTNER ARGENX SE (EURONEXT & NASDAQ: ARGX), A GLOBAL IMMUNOLOGY COMPANY COMMITTED TO IMPROVING THE LIVES OF PEOPLE SUFFERING FROM SEVERE AUTOIMMUNE DISEASES AND CANCER, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED VYVGART™ (EFGARTIGIMOD ALFA-FCAB) FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN ADULT PATIENTS WHO ARE ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE. THESE PATIENTS REPRESENT APPROXIMATELY 85% OF THE TOTAL GMG POPULATION1. WITH THIS REGULATORY MILESTONE, VYVGART IS THE FIRST AND ONLY FDA-APPROVED NEONATAL FC RECEPTOR (FCRN) BLOCKER.
|
ZAI LAB PARTNER ARGENX ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF VYVGART™ (EFGARTIGIMOD ALFA-FCAB) IN GENERALIZED MYASTHENIA GRAVIS
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-16 04:43:00
| null |
NUZYRA DEMONSTRATED EFFICACY AGAINST COMMON PATHOGENS IN THREE PHASE 3 STUDIES, INCLUDING PATHOGENS RESISTANT TO OTHER ANTIBIOTIC CLASSES AS A POTENTIAL BEST-IN-CLASS TETRACYCLINE
|
CHINA NMPA APPROVES NUZYRA® AS A CATEGORY 1 INNOVATIVE DRUG FOR THE TREATMENT OF PATIENTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) AND ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI)
|
ZLAB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.